PDF(Pubmed)
Abstract：
UNASSIGNED: Allergic rhinitis (AR) is a respiratory immune system disorder characterized by dysregulation of immune responses. Within the context of AR, gut microbiota and its metabolites have been identified as contributors to immune modulation. These microorganisms intricately connect the respiratory and gut immune systems, forming what is commonly referred to as the gut-lung axis. Xiaoqinglong Decoction (XQLD), a traditional Chinese herbal remedy, is widely utilized in traditional Chinese medicine for the clinical treatment of AR. In this study, it is hypothesized that the restoration of symbiotic microbiota balance within the gut-lung axis plays a pivotal role in supporting the superior long-term efficacy of XQLD in AR therapy. Therefore, the primary objective of this research is to investigate the impact of XQLD on the composition and functionality of the gut microbiota in a murine model of AR.
UNASSIGNED: An ovalbumin-sensitized mouse model to simulate AR was utilized, the improvement of AR symptoms after medication was investigated, and high-throughput sequencing was employed to analyze the gut microbiota composition.
UNASSIGNED: XQLD exhibited substantial therapeutic effects in AR mice, notably characterized by a significant reduction in allergic inflammatory responses, considerable alleviation of nasal symptoms, and the restoration of normal nasal function. Additionally, following XQLD treatment, the disrupted gut microbiota in AR mice displayed a tendency toward restoration, showing significant differences compared to the Western medicine (loratadine) group.
UNASSIGNED: This results revealed that XQLD may enhance AR allergic inflammatory responses through the regulation of intestinal microbiota dysbiosis in mice, thus influencing the dynamics of the gut-lung axis. The proposal of this mechanism provides a foundation for future research in this area.
UNASSIGNED: An ovalbumin-sensitized mouse model to simulate AR was utilized, the improvement of AR symptoms after medication was investigated, and high-throughput sequencing was employed to analyze the gut microbiota composition.
UNASSIGNED: XQLD exhibited substantial therapeutic effects in AR mice, notably characterized by a significant reduction in allergic inflammatory responses, considerable alleviation of nasal symptoms, and the restoration of normal nasal function. Additionally, following XQLD treatment, the disrupted gut microbiota in AR mice displayed a tendency toward restoration, showing significant differences compared to the Western medicine (loratadine) group.
UNASSIGNED: This results revealed that XQLD may enhance AR allergic inflammatory responses through the regulation of intestinal microbiota dysbiosis in mice, thus influencing the dynamics of the gut-lung axis. The proposal of this mechanism provides a foundation for future research in this area.
摘要：
过敏性鼻炎(AR)是以免疫应答失调为特征的呼吸免疫系统病症。在AR的背景下，肠道微生物群及其代谢物已被确定为免疫调节的贡献者。这些微生物错综复杂地连接着呼吸道和肠道免疫系统，形成通常所说的肠-肺轴。小青龙汤（XQLD），一种传统的中草药，中医在临床上广泛用于AR的治疗。在这项研究中,据推测,肠-肺轴内共生微生物群平衡的恢复在支持XQLD在AR治疗中的长期疗效方面起着关键作用.因此,本研究的主要目的是研究XQLD对AR小鼠模型中肠道菌群组成和功能的影响.
■使用卵清蛋白致敏小鼠模型来模拟AR，研究了药物治疗后AR症状的改善情况，采用高通量测序技术分析肠道菌群组成。
■XQLD在AR小鼠中表现出实质性的治疗作用，其特点是过敏性炎症反应显著减少，显著缓解鼻部症状，恢复正常的鼻功能.此外,在XQLD治疗之后，AR小鼠肠道微生物群的破坏显示出恢复的趋势，显示与西药(氯雷他定)组相比有显著差异。
■该结果表明，XQLD可能通过调节小鼠肠道菌群失调来增强AR过敏性炎症反应，从而影响肠-肺轴的动力学。该机制的提出为该领域的未来研究提供了基础。
■使用卵清蛋白致敏小鼠模型来模拟AR，研究了药物治疗后AR症状的改善情况，采用高通量测序技术分析肠道菌群组成。
■XQLD在AR小鼠中表现出实质性的治疗作用，其特点是过敏性炎症反应显著减少，显著缓解鼻部症状，恢复正常的鼻功能.此外,在XQLD治疗之后，AR小鼠肠道微生物群的破坏显示出恢复的趋势，显示与西药(氯雷他定)组相比有显著差异。
■该结果表明，XQLD可能通过调节小鼠肠道菌群失调来增强AR过敏性炎症反应，从而影响肠-肺轴的动力学。该机制的提出为该领域的未来研究提供了基础。
